NCT05942807 Observational Monocentric Study on Biliary Tract Cancer (BABEL)
| NCT ID | NCT05942807 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
| Condition | Biliary Tract Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 560 participants |
| Start Date | 2021-05-15 |
| Primary Completion | 2025-05-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 560 participants in total. It began in 2021-05-15 with a primary completion date of 2025-05-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
BABEL is an observational, single-center, prospective study about patients affected by biliary tract cancers (BTC) treated at the Medical Oncology Unit of the FPUAG - IRCCS.
Eligibility Criteria
Inclusion Criteria: * Patients with biliary tract cancer; * Patients with radiological evident disease; * Patients \>18 anni; * Written informed consent; * Patients with at least one oncological visit. Exclusion Criteria: * Patients without available clinical data; * Patients without histological diagnosis of BTC; * Patients without written informed consent.
Contact & Investigator
Lisa Salvatore, MD, PhD
PRINCIPAL INVESTIGATOR
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Frequently Asked Questions
Who can join the NCT05942807 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Biliary Tract Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05942807 currently recruiting?
Yes, NCT05942807 is actively recruiting participants. Contact the research team at lisa.salvatore@policlinicogemelli.it for enrollment information.
Where is the NCT05942807 trial being conducted?
This trial is being conducted at Roma, Italy.
Who is sponsoring the NCT05942807 clinical trial?
NCT05942807 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The principal investigator is Lisa Salvatore, MD, PhD at Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The trial plans to enroll 560 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.